185P The combined role of patients (pts) gender and disease etiology on unresectable HCC (uHCC) first-line (1L) treatment outcome

S. Cesario; V. Genovesi; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Fabian Finkelmeier; Changhoon Yoo; José Presa; Massimo Iavarone; Fabio Marra; Francesco Giuseppe Foschi; Emiliano Tamburini; Silvia Lonardi; Fabio Piscaglia; Francesca Salani; Caterina Vivaldi; A. Casadei Gardini; Gianluca Masi

doi:10.1016/j.annonc.2024.05.194

Related publications

Article2023

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Masatoshi Kudo, Richard S. Finn, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel, Shukui Qin

Article2017

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean–Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo

Article2024

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

T.R. Jeffry Evans, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Shukui Qin, Taisuke Hoshi, Ryuji Tamaki, Yasuhiro Funahashi, Chinyere E. Okpara, Koji Sagane, Dongyuan Xing, Yukinori Minoshima, Richard S. Finn

Article2022

Addition of tyrosine kinase inhibitors (TKIs) in patients (pts) with unresectable hepatocellular carcinoma (HCC) who progress on first-line immunotherapy (IO).

Linda Wu, Roger Esteban, Michelle Rudshteyn, Myron Schwartz, Max W. Sung, Josep M. Llovet, Deirdre Jill Cohen

Journal of Clinical Oncology

Article2018

Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Riccardo Lencioni, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Fabio Piscaglia, Guohong Han, Masafumi Ikeda, Krzysztof Simon, Д. В. Комов, Xuenong Ouyang, T.R. Jeffry Evans, Max W. Sung, Terri A. Binder, Andrew Damon, Silvija Kraljevic, Min Ren, Baek‐Yeol Ryoo